Business Wire

ProRail strengthens nationwide rail network with Adtran ALM fiber monitoring solution

9.4.2026 14:00:00 CEST | Business Wire | Press Release

Share

Adtran today announced that ProRail, the operator of the Dutch railway network, has deployed its ALM in‑service fiber monitoring solution to protect the integrity of its nationwide fiber infrastructure. The technology supports critical ICT systems used for timetabling, incident management, maintenance and new construction planning. With real‑time insight into fiber health across its 4,600km backbone network, ProRail can identify and address issues before they impact rail operations. This approach reflects a growing demand for in‑service fiber assurance across large‑scale transport and other critical infrastructure networks. The deployment was delivered in collaboration with TrueCom, a specialist in critical network and fiber optic infrastructures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260409025433/en/

Adtran’s fiber monitoring solution is helping ProRail gain real-time insight into its network and deliver even greater service reliability to passengers.

“A reliable communication network is essential for ensuring that trains run safely and on time,” said Michael Verhaar, solution architect for passive telecom infrastructure at ProRail. “By using ALM to continuously monitor our fiber optic infrastructure, we gain real-time insight into the condition of our network and can identify issues before they impact operations. This enables us to plan maintenance in a much more targeted way. The result is improved reliability, more efficient use of resources, and a rail network that operates with even greater cost-efficiency to deliver maximum value for the traveling public.”

ProRail has deployed Adtran’s 16-port ALM in-service fiber monitoring solution to monitor the physical integrity of its nationwide backbone fiber network. The solution was selected for its simplicity of use, high measurement accuracy, compact form factor and flexible deployment options, enabling precise monitoring of critical fiber – all without adding operational complexity. Through an intuitive graphical user interface, ALM provides immediate alerts that pinpoint the exact location of fiber breaks, degradation and abnormal attenuation. By delivering 24/7 network visibility alongside long‑term performance data, the solution supports more targeted repairs while reducing unnecessary truck rolls.

“ProRail operates one of Europe’s busiest railway networks, where communications infrastructure must perform consistently under constant operational pressure,” commented Stuart Broome, GM of EMEA and APAC sales at Adtran. “The insights our ALM provides enable ProRail to make more informed decisions about when and where support teams are required. Without the need for a costly and complex software suite, ALM delivers advanced in‑service monitoring and gives operators the flexibility to integrate fiber assurance into existing operational systems, supporting a smarter long‑term strategy that strengthens network resilience while helping to reduce operational costs.”

“Working closely with ProRail and Adtran, we focused on delivering a solution that integrates smoothly into existing workflows,” noted Dhieradj Ramanand, optical solutions sales manager at TrueCom. “With round-the-clock monitoring of the physical fiber layer, ProRail gains deep insight into the state of its network. This enables the transition from reactive troubleshooting to proactive, data-driven maintenance, improving both the reliability and efficiency of the infrastructure. It’s a solution that supports long-term infrastructure management while allowing ProRail’s teams to work more efficiently.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by 
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409025433/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Rob Fink
+1 646 809 4048
investor.relations@adtran.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye